StockWireNews
Could This Tiny Float Nasdaq Biotech Become A Major Breakout Target As Its Game-Changing News Circulates?
Full Report Arrives At 9:30AM EST Tomorrow
Sign Up To My SMS Update System - Directions Below
February 1st
Greetings Readers,
Let's slow things down for a minute.
Tomorrow at 9:30AM EST, I'm bringing you a new Nasdaq breakout idea.
Why is this one special? I'll tell you.
According to Cary Gross, the director of the National Clinical Scholars Program at Yale, "The U.S. is spending over $200Bn per year on cancer care—roughly $600 per person, in comparison to the average of $300 per person across other high-income countries."(1)
Over $200Bn...
That's a lot of scratch. It's also why I like to keep an eye on biotechnology companies.
One company in particular is flying under Wall Street's radar right now, but I'm not sure for how much longer.
With the company advancing multiple cancer therapeutic candidates in their pipeline, it may be just a matter of time until they go from "little known" to "well known" if you get what I'm saying.
But before they receive a broader audience, I want you to get them on your radar.
So to help familiarize you with this profile, here's some key details to know ahead of your upcoming report.
New Nasdaq Biotech - 3 Key Potential Catalysts To Know Now
#1. This is a low float profile with fewer than 5Mn shares in its float which means volatility is always on watch.
#2. The company has some really hot recent news starting to make the rounds. With only one month under its belt, 2023 could become a game-changing year for this Nasdaq profile.
#3. As of writing, this profile is trading above 3 key lines of potential support in its 50-Day Simple Moving Average (SMA), its 200-Day SMA, and its 13-Day Exponential Moving Average (EMA).
If potential support continues to grow at those levels, they could act as the building blocks towards a strong vertical move going forward.
When time permits, do this:
